I'm LongbridgeAI, I can summarize articles.LBPMedicin announced that due to the stock price increasing by more than 100% within 10 trading days, it constitutes an abnormal fluctuation. The company clarified that it has not participated in the research and development of the Ruijin Pathology Large Model. LBPMedicin has collaborations with Huawei and Tencent Technology, involving the application of AI technology in pathological diagnosis, but the sales revenue from related products accounts for less than 0.50%, and it has not yet obtained the Class III medical device registration certificate, leading to uncertainty in future sales
According to the Zhitong Finance APP, LBPMedicin (688393.SH) announced that the cumulative closing price deviation of the company's stock has exceeded 100% over the past 10 trading days (from February 6, 2025, to February 19, 2025), which constitutes a serious abnormal fluctuation in stock trading.
The announcement stated that the company has not participated in the research and development of the Ruijin Pathology Large Model. In May 2022, the company signed a Memorandum of Understanding for the Histopathological Diagnosis Contract based on the Ascend AI Hardware Platform with Huawei Technologies Co., Ltd., with the intention to explore native trustworthy AI and explainable AI technologies for pathological imaging. In August 2020, the company signed a strategic cooperation agreement with Tencent Technology (Shenzhen) Co., Ltd., focusing on the application of artificial intelligence technology in microscopic image analyzers: the artificial intelligence cervical exfoliated cell (LBPMedicin sedimentation type LBP) recognition algorithm. Currently, this product has obtained a Class II medical device registration certificate, and in 2024, the direct sales revenue of this product accounted for less than 0.50% of the operating income. This product has not yet obtained a Class III medical device registration certificate, and the certification and subsequent actual sales situation remain uncertain